Skip to main content
Fig. 4 | Cardio-Oncology

Fig. 4

From: Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance

Fig. 4

Total immune checkpoint inhibitor (ICI) cycles, time interval, and survival probability between first exposure to clinical diagnosis and death in reclassified patients. A Comparison of total ICI cycles. B Percent of patients with clinical diagnosis for myocarditis following cycle 1 of ICI treatment. C Percent survival probability of patients at 15 months following cycle 1 of ICI treatment. The n are defined as Possible (n = 6), Probable (n = 9), and Definite (n = 11) using the reclassified myocarditis patient cohorts. Open circle symbols represent censored patients in Possible (n = 5), Probable (n = 2), and Definite (n = 5) cohorts. Data were compared using the Mantel-Cox log-rank test with P < 0.05 being considered statistically significant

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us